Table 1 DRI and CI values for the effects of combining BKM120 with olaparib on the proliferation of MDA-MB-231 cells.

From: BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression

Inhibition ratio

BKM120 (μM)

Olaparib (μM)

Ratio (1:6)

BKM120 (DRI)

Olaparib (DRI)

CI value

BKM120 (μM)

Olaparib (μM)

0.50

2.21 ± 0.17

16.6 ± 0.82

0.99 ± 0.05**

5.94 ± 0.30##

2.23 ± 0.21

2.79 ± 0.19

0.80 ± 0.09

0.60

3.46 ± 0.18

25.1 ± 2.02

1.32 ± 0.06**

7.92 ± 0.36##

2.57 ± 0.18

3.24 ± 0.30

0.70 ± 0.08

0.70

5.03 ± 0.27

36.5 ± 1.96

1.70 ± 0.07**

10.2 ± 0.42##

2.87 ± 0.18

3.34 ± 0.22

0.65 ± 0.06

0.80

6.44 ± 0.71

40.2 ± 1.61

1.92 ± 0.11**

11.5 ± 0.66##

3.35 ± 0.42

3.49 ± 0.24

0.58 ± 0.08

0.90

8.78 ± 0.83

49.7 ± 1.64

2.36 ± 0.13**

14.2 ± 0.78##

3.81 ± 0.41

3.51 ± 0.23

0.55 ± 0.07

0.95

10.9 ± 0.97

55.3 ± 2.31

2.62 ± 0.12**

15.7 ± 0.72##

4.16 ± 0.42

3.52 ± 0.22

0.52 ± 0.06

  1. *P < 0.05 and **P < 0.01 compared to BKM120 alone treated group, #P < 0.05 and ##P < 0.01 compared to olaparib alone treated group.
Back to article page